RLI Corp. Reports 30th Consecutive Year of Underwriting Profitability with Strong 2025 Financials
RLI is trading near its 52-week low of $55.8 (8.6% above the low) on light trading volume (0.2× avg).
Summary
RLI Corp. reported strong full-year 2025 financial results, marking its 30th consecutive year of underwriting profitability, with significant increases in net earnings and underwriting income, and a notable extraordinary dividend payment.
Key Events · Earnings and Guidance · RLI
-
Exceptional 2025 Financial Performance
Net earnings increased to $403.3 million from $345.8 million in 2024, driven by a 6% rise in net premiums earned and a 12% increase in net investment income.
-
30th Consecutive Year of Underwriting Profit
The company achieved an 83.6% combined ratio in 2025, improving from 86.2% in 2024, reflecting disciplined underwriting and lower catastrophe losses of $30 million compared to $76 million in the prior year.
-
Significant Capital Return to Shareholders
RLI Corp. paid $2.00 per share in special cash dividends in December 2025 and received regulatory approval for $151 million in extraordinary dividends from its principal insurance subsidiary.
-
Strong Balance Sheet and Capital Management
Total shareholders' equity grew to $1.78 billion from $1.52 billion in 2024, supported by positive operating cash flow and a diversified investment portfolio.
Analysis · RLI · Finance
This 10-K filing confirms and provides comprehensive audited details for RLI Corp.'s strong financial performance in 2025, following the preliminary positive announcement on January 21, 2026. The company's achievement of its 30th consecutive year of underwriting profitability, coupled with increased net earnings and a significantly improved combined ratio, underscores its robust operational discipline. The substantial extraordinary dividend payment in 2025 highlights effective capital management and a commitment to shareholder returns. Investors should view these results as a strong affirmation of the company's business model and financial health, reinforcing the positive sentiment from recent insider buying.
At the time of this filing, RLI was trading at $60.59 on NYSE in the Finance sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $55.80 to $81.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.